15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for PCSA yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $2.16 current
Highest Target—
Average Target—
Lowest Target—
PCSA analyst recommendation trends
86420
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Strong BuyBuyHoldSellStrong Sell
RATING
MAR
APR
MAY
JUN
JUL
AUG
Strong Buy
0
0
0
0
0
0
Buy
1
1
1
1
1
1
Hold
0
0
0
0
0
0
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
1
1
1
1
1
1
As of Aug, 1 of 1 firms rate PCSA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PCSA EPS & revenue forecast
EPS · THIS QUARTER
$-1.50
Range $-1.50 – $-1.50 · 1 analysts · -92% YoY
Next period, 1 analysts expect Processa Pharmaceuticals Inc to earn $-1.50 a share (range $-1.50 – $-1.50), versus $-18.50 a year earlier. , growing to $-3.75 the year after.
REVENUE · THIS QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —)., rising to $0 next year.
Top analysts covering Processa Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PCSA.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #312
Buy
$1.00-53.7% to target
Overall win rate
36%
+ Follow
#2
NR
Naz Rahman
Maxim Group
Hold
No targeton PCSA
Coverage
—
+ Follow
#3
RS
Ram Selvaraju
H.C. Wainwright
Buy
$25.00+1057.4% to target
Coverage
—
+ Follow
PCSA stock forecast FAQ
Who is the most accurate analyst covering PCSA?+
Among analysts who currently cover PCSA, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #312). Their current call is Buy with a $1.00 target.
What is Processa Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-1.50 per share (range $-1.50 – $-1.50) across 1 analysts, rising to $-3.75 the following year.
How much revenue is Processa Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is — (range — – —), growing to $0 next year.
Have analysts been upgrading or downgrading PCSA lately?+
As of Aug, 1 of 1 firms rate PCSA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PCSA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
